Lipocine Inc
$ 2.13
0.00%
07 Aug - close price
- Market Cap 17,560,300 USD
- Current Price $ 2.13
- High / Low $ 2.26 / 2.12
- Stock P/E N/A
- Book Value 3.05
- EPS -1.85
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.33 %
- ROE -0.54 %
- 52 Week High 12.37
- 52 Week Low 1.81
About
Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceuticals for the treatment of metabolic and endocrine disorders. The company is headquartered in Salt Lake City, Utah.
Analyst Target Price
$6.00
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-04 | 2026-05-07 | 2026-03-09 | 2025-11-06 | 2025-08-05 | 2025-05-08 | 2025-03-13 | 2024-11-07 | 2024-08-08 | 2024-05-09 | 2024-03-07 | 2023-11-08 |
| Reported EPS | -0.32 | -0.54 | -0.42 | -0.59 | -0.41 | -0.35 | 0.33 | -0.44 | -0.56 | 0.66 | -0.42 | -1.26 |
| Estimated EPS | -0.47 | -0.48 | -0.61 | -0.54 | -0.4 | -0.35 | -0.4 | -0.48 | -0.78 | -0.68 | -0.47 | -0.6 |
| Surprise | 0.15 | -0.06 | 0.19 | -0.05 | -0.01 | 0 | 0.73 | 0.04 | 0.22 | 1.34 | 0.05 | -0.66 |
| Surprise Percentage | 31.9149% | -12.5% | 31.1475% | -9.2593% | -2.5% | 0% | 182.5% | 8.3333% | 28.2051% | 197.0588% | 10.6383% | -110% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: LPCN
2026-08-07 21:10:02
Lipocine director Michael Grissinger has filed an initial Form 3 statement regarding beneficial ownership. This filing is tied to an event reported on August 3, 2026, and was publicly disclosed on August 7, 2026, via the SEC's EDGAR system. The news brief was generated by AI based on content from Lipocine Inc.
2026-08-07 20:10:02
Lipocine Inc. (NASDAQ: LPCN) director Michael Grissinger was awarded 2,000 stock options on August 3, 2026, with an exercise price of $2.11 per share and an expiration date of August 3, 2036. The options have a vesting schedule, with one-third vesting on August 3, 2027, and the remainder vesting monthly over the subsequent two years. This transaction was reported on a Form 4 and was not made under a Rule 10b5-1 trading plan.
2026-08-07 20:10:02
Lipocine Inc. director Michael Grissinger has filed an initial statement of beneficial ownership (Form 3). This filing indicates that Grissinger is a director but not an officer or a ten percent owner of the company, and it reports no current equity holdings or insider transactions. The document serves to establish his insider status without reflecting any immediate trading activity or significant ownership stake.
2026-08-07 17:10:02
Lipocine Inc (LPCN) has an earnings forecast score of 7.00, ranking 306th in the Biotechnology & Medical Research industry. Analysts have set an average price target of $6.88, with a "Buy" rating based on the opinions of 2 analysts. The company's expected revenue for the next quarter is $159.50K, and the expected EPS is -$0.40, following a previous quarter's EPS of -$0.54 against a market expectation of -$0.32.
2026-08-05 07:42:23
Lipocine (NASDAQ: LPCN) reported a significant decline in Q2 2026 revenue to $190,099, primarily due to the absence of license revenue from the prior year, though TLANDO royalties increased. The company's net loss widened to $2.6 million, and attention is now focused on an upcoming FDA meeting and a new clinical trial for LPCN 1154 after its Phase 3 trial failed to meet its primary endpoint. Increased R&D spending and share count expansion are also key factors for investors to monitor.
2026-08-04 18:11:36
This article provides a comprehensive overview of Lipocine Inc. (NASDAQ: LPCN), including its current stock price, fundamental financial data, and peer comparison. It details the company's income statement, balance sheet, and cash flow for several years, highlighting its clinical-stage biopharmaceutical focus on CNS disorders and various pipeline candidates. The information is sourced from EOD Historical Data and intended for general informational purposes.
